Brief: Sensei Biotherapeutics Announces First Patient Dosed In Phase 1/2 Clinical Trial Of Sns-101, A Conditionally Active Vista-Blocking Antibody, For The Treatment Of Advanced Solid Tumors
01/06/2023 12:31
June 1 (Reuters) - Sensei Biotherapeutics Inc SNSE.O :
* SENSEI BIOTHERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
PHASE
1/2 CLINICAL TRIAL OF SNS-101, A CONDITIONALLY ACTIVE
VISTA-BLOCKING ANTIBODY, FOR THE TREATMENT OF ADVANCED SOLID
TUMORS
* SENSEI BIOTHERAPEUTICS INC - TOPLINE PHASE 1 MONOTHERAPY
AND
INITIAL COMBINATION DATA EXPECTED IN 2024
Source text for Eikon: ID:nGNX8lfRQS
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics
See all newsU.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
Faeth Therapeutics rises after FDA grants fast-track status for cancer drug
Brief: Faeth Therapeutics Announces FDA Grant Of Fast Track Designation For Piktor Plus Paclitaxel In Biomarker-Selected Advanced Endometrial Cancer
Brief: Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments